Dasatinib increases endothelial permeability leading to pleural effusion

Carole Phan, Etienne-Marie Jutant, Ly Tu, Raphaël Thuillet, Andrei Seferian, David Montani, Alice Huertas, Jan van Bezu, Fabian Breijer, Anton Vonk Noordegraaf, Marc Humbert, Jurjan Aman, Christophe Guignabert

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Pleural effusion is a frequent side-effect of dasatinib, a second-generation tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying mechanisms remain unknown. We hypothesised that dasatinib alters endothelial integrity, resulting in increased pulmonary vascular endothelial permeability and pleural effusion.To test this, we established the first animal model of dasatinib-related pleural effusion, by treating rats with a daily regimen of high doses of dasatinib (10 mg·kg-1·day-1 for 8 weeks).Pleural ultrasonography revealed that rats chronically treated with dasatinib developed pleural effusion after 5 weeks. Consistent with these in vivo observations, dasatinib led to a rapid and reversible increase in paracellular permeability of human pulmonary endothelial cell monolayers as reflected by increased macromolecule passage, loss of vascular endothelial cadherin and zonula occludens-1 from cell-cell junctions, and the development of actin stress fibres. These results were replicated using human umbilical vein endothelial cells and confirmed by decreased endothelial resistance. Interestingly, we demonstrated that this increased endothelial permeability is a reactive oxygen species (ROS)-dependent mechanism in vitro and in vivo using a cotreatment with an antioxidant agent, N-acetylcysteine.This study shows that dasatinib alters pulmonary endothelial permeability in a ROS-dependent manner in vitro and in vivo leading to pleural effusion.

Original languageEnglish
JournalEuropean Respiratory Journal
Volume51
Issue number1
DOIs
Publication statusPublished - Jan 2018

Cite this

Phan, C., Jutant, E-M., Tu, L., Thuillet, R., Seferian, A., Montani, D., ... Guignabert, C. (2018). Dasatinib increases endothelial permeability leading to pleural effusion. European Respiratory Journal, 51(1). https://doi.org/10.1183/13993003.01096-2017
Phan, Carole ; Jutant, Etienne-Marie ; Tu, Ly ; Thuillet, Raphaël ; Seferian, Andrei ; Montani, David ; Huertas, Alice ; Bezu, Jan van ; Breijer, Fabian ; Vonk Noordegraaf, Anton ; Humbert, Marc ; Aman, Jurjan ; Guignabert, Christophe. / Dasatinib increases endothelial permeability leading to pleural effusion. In: European Respiratory Journal. 2018 ; Vol. 51, No. 1.
@article{94d73535e403434b82632258ab2862ff,
title = "Dasatinib increases endothelial permeability leading to pleural effusion",
abstract = "Pleural effusion is a frequent side-effect of dasatinib, a second-generation tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying mechanisms remain unknown. We hypothesised that dasatinib alters endothelial integrity, resulting in increased pulmonary vascular endothelial permeability and pleural effusion.To test this, we established the first animal model of dasatinib-related pleural effusion, by treating rats with a daily regimen of high doses of dasatinib (10 mg·kg-1·day-1 for 8 weeks).Pleural ultrasonography revealed that rats chronically treated with dasatinib developed pleural effusion after 5 weeks. Consistent with these in vivo observations, dasatinib led to a rapid and reversible increase in paracellular permeability of human pulmonary endothelial cell monolayers as reflected by increased macromolecule passage, loss of vascular endothelial cadherin and zonula occludens-1 from cell-cell junctions, and the development of actin stress fibres. These results were replicated using human umbilical vein endothelial cells and confirmed by decreased endothelial resistance. Interestingly, we demonstrated that this increased endothelial permeability is a reactive oxygen species (ROS)-dependent mechanism in vitro and in vivo using a cotreatment with an antioxidant agent, N-acetylcysteine.This study shows that dasatinib alters pulmonary endothelial permeability in a ROS-dependent manner in vitro and in vivo leading to pleural effusion.",
author = "Carole Phan and Etienne-Marie Jutant and Ly Tu and Rapha{\"e}l Thuillet and Andrei Seferian and David Montani and Alice Huertas and Bezu, {Jan van} and Fabian Breijer and {Vonk Noordegraaf}, Anton and Marc Humbert and Jurjan Aman and Christophe Guignabert",
note = "Copyright {\circledC}ERS 2018.",
year = "2018",
month = "1",
doi = "10.1183/13993003.01096-2017",
language = "English",
volume = "51",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

Phan, C, Jutant, E-M, Tu, L, Thuillet, R, Seferian, A, Montani, D, Huertas, A, Bezu, JV, Breijer, F, Vonk Noordegraaf, A, Humbert, M, Aman, J & Guignabert, C 2018, 'Dasatinib increases endothelial permeability leading to pleural effusion' European Respiratory Journal, vol. 51, no. 1. https://doi.org/10.1183/13993003.01096-2017

Dasatinib increases endothelial permeability leading to pleural effusion. / Phan, Carole; Jutant, Etienne-Marie; Tu, Ly; Thuillet, Raphaël; Seferian, Andrei; Montani, David; Huertas, Alice; Bezu, Jan van; Breijer, Fabian; Vonk Noordegraaf, Anton; Humbert, Marc; Aman, Jurjan; Guignabert, Christophe.

In: European Respiratory Journal, Vol. 51, No. 1, 01.2018.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Dasatinib increases endothelial permeability leading to pleural effusion

AU - Phan, Carole

AU - Jutant, Etienne-Marie

AU - Tu, Ly

AU - Thuillet, Raphaël

AU - Seferian, Andrei

AU - Montani, David

AU - Huertas, Alice

AU - Bezu, Jan van

AU - Breijer, Fabian

AU - Vonk Noordegraaf, Anton

AU - Humbert, Marc

AU - Aman, Jurjan

AU - Guignabert, Christophe

N1 - Copyright ©ERS 2018.

PY - 2018/1

Y1 - 2018/1

N2 - Pleural effusion is a frequent side-effect of dasatinib, a second-generation tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying mechanisms remain unknown. We hypothesised that dasatinib alters endothelial integrity, resulting in increased pulmonary vascular endothelial permeability and pleural effusion.To test this, we established the first animal model of dasatinib-related pleural effusion, by treating rats with a daily regimen of high doses of dasatinib (10 mg·kg-1·day-1 for 8 weeks).Pleural ultrasonography revealed that rats chronically treated with dasatinib developed pleural effusion after 5 weeks. Consistent with these in vivo observations, dasatinib led to a rapid and reversible increase in paracellular permeability of human pulmonary endothelial cell monolayers as reflected by increased macromolecule passage, loss of vascular endothelial cadherin and zonula occludens-1 from cell-cell junctions, and the development of actin stress fibres. These results were replicated using human umbilical vein endothelial cells and confirmed by decreased endothelial resistance. Interestingly, we demonstrated that this increased endothelial permeability is a reactive oxygen species (ROS)-dependent mechanism in vitro and in vivo using a cotreatment with an antioxidant agent, N-acetylcysteine.This study shows that dasatinib alters pulmonary endothelial permeability in a ROS-dependent manner in vitro and in vivo leading to pleural effusion.

AB - Pleural effusion is a frequent side-effect of dasatinib, a second-generation tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying mechanisms remain unknown. We hypothesised that dasatinib alters endothelial integrity, resulting in increased pulmonary vascular endothelial permeability and pleural effusion.To test this, we established the first animal model of dasatinib-related pleural effusion, by treating rats with a daily regimen of high doses of dasatinib (10 mg·kg-1·day-1 for 8 weeks).Pleural ultrasonography revealed that rats chronically treated with dasatinib developed pleural effusion after 5 weeks. Consistent with these in vivo observations, dasatinib led to a rapid and reversible increase in paracellular permeability of human pulmonary endothelial cell monolayers as reflected by increased macromolecule passage, loss of vascular endothelial cadherin and zonula occludens-1 from cell-cell junctions, and the development of actin stress fibres. These results were replicated using human umbilical vein endothelial cells and confirmed by decreased endothelial resistance. Interestingly, we demonstrated that this increased endothelial permeability is a reactive oxygen species (ROS)-dependent mechanism in vitro and in vivo using a cotreatment with an antioxidant agent, N-acetylcysteine.This study shows that dasatinib alters pulmonary endothelial permeability in a ROS-dependent manner in vitro and in vivo leading to pleural effusion.

U2 - 10.1183/13993003.01096-2017

DO - 10.1183/13993003.01096-2017

M3 - Article

VL - 51

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -